OPTH Overview

Optimi Health Corp. is a commercial-stage pharmaceutical company. The Company focuses on manufacturing and distributing good manufacturing practices (GMP) grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, the Company produces validated Methylenedioxymethamphetamine hydrochloride (MDMA) and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada. It supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products prescribed to patients in Australia under the country's authorized prescriber scheme and accessible in Canada through the special access program. With its vertically integrated approach, the Company owns and operates two purpose-built 10,000-square-foot licensed production sites in Princeton, British Columbia and holds a Drug Establishment Licence (DEL), as issued by Health Canada.

Wall Street analysts forecast OPTH stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for OPTH is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Optimi Health Corp revenue for the last quarter amounts to 99.50K USD, increased 62.47

Optimi Health Corp. EPS for the last quarter amounts to -14.83 USD, increased 24616.67

Optimi Health Corp (OPTH) has 0 emplpoyees as of June 24 2026.

Today OPTH has the market capitalization of 28.27M USD.